BlackRock Fund Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

BlackRock Fund Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2K	Buy	19 +6	+46%	+$623	﹤0.01%	4165
2016 Q3	$1K	Buy	13 +1	+8%	+$92	﹤0.01%	4246
2016 Q2	$1K	Sell	12 -331	-97%	-$29.7K	﹤0.01%	4304
2016 Q1	$19K	Sell	343 -22	-6%	-$1.7K	﹤0.01%	3905
2015 Q4	$46K	Sell	365 -5	-1%	-$3.3K	﹤0.01%	3898
2015 Q3	$268K	Buy	370 +84	+29%	+$90.2K	﹤0.01%	3373
2015 Q2	$232K	Buy	+286	New	+$184K	﹤0.01%	3467

Other funds holding EVFM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

WAS

WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock Fund Advisors's EVFM Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Evofem Biosciences, Inc. Common Stock (EVFM) stake by 46% in Q4 2016, buying an estimated $623 and bringing the position to 19 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

BlackRock Fund Advisors first reported a position in EVFM in Q2 2015 and has held it in 7 quarters since. The position peaked at $268K in Q3 2015. 14 funds tracked by Wall St. Rank hold EVFM as of Q4 2016.

BlackRock Fund Advisors held 19 shares of Evofem Biosciences, Inc. Common Stock worth $2K as of Q4 2016.
BlackRock Fund Advisors bought 6 Evofem Biosciences, Inc. Common Stock shares in Q4 2016, an estimated $623.
Evofem Biosciences, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4165 holding.
BlackRock Fund Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $268K in Q3 2015.
14 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.